Galderma’s menopause skin survey and injectable trial, with their evidence limits and the AAD’s guidance on routine care and assessment.
On October 13, 2026, Galderma published a company press release reporting a survey on menopause-related skin changes and a company-supported trial of injectable treatments.
The American Academy of Dermatology (AAD) already recognises that menopause can bring dry, slack or thin skin. The relevant shift is therefore not the introduction of a previously unknown link between menopause and skin. It is the suggestion that this knowledge has not reached many women navigating the transition.
Galderma’s survey challenges an ageing-only explanation among respondents, not an established medical consensus that excludes hormones. That distinction matters because a gap in awareness calls for clearer information before it calls for a different treatment.
For a reader noticing changes in her skin, the useful question is not whether she has chosen the wrong label. It is whether the explanation she has been offered leaves room for menopause and a discussion of her actual concern. Refemina’s guide to how midlife skin changes develop provides wider context for that conversation.
Galderma said Perspectus Global surveyed 5,090 women who had experienced or were experiencing perimenopause or menopause. Respondents were in the UK, US, Brazil and China. Fieldwork ran from August 25 to September 1, 2026.
The most useful editorial signal is the combination of buying and feeling overwhelmed. A woman can be actively trying to care for her skin while still lacking an explanation that makes sense to her. The case for clearer education does not require casting those purchases as foolish or treating concern about appearance as trivial.
Wanting clearer information is a legitimate outcome in itself. It gives this story relevance beyond the treatment products named in the same release.
The question is also how that information is delivered. An explanation of menopause-related skin change should expand a woman’s understanding, not make her feel that her face is a problem requiring correction. Refemina treats appearance and confidence as legitimate parts of midlife health without making a younger look the measure of success.
That leaves room for different aims in a consultation. Understanding why skin feels dry is one concern; deciding whether to pursue an aesthetic change is another. Keeping those aims separate is a useful editorial response to the reported advice overload, because education should not arrive with an implied obligation to buy.
Galderma also described an eight-month investigator-initiated trial led by Dr. Andreas Nikolis and supported by the company. It evaluated Restylane Skinboosters and Sculptra in menopausal women on the face and décolletage. The comparison concerned treatment order: Skinboosters-then-Sculptra versus Sculptra-then-Skinboosters.
The evidence needs to be separated into questions about awareness, treatment outcomes and treatment decisions. Galderma is presenting both the survey and the trial while positioning menopausal skin as an area for education and aesthetic treatment. That commercial context is part of how the findings should be read.
On the survey side, the release gives no detail about sampling, recruitment or weighting. It also omits question wording and information establishing representativeness. The percentages describe this survey’s respondents rather than estimates that necessarily apply to all women experiencing menopause.
Calling a change “menopause-related” reflects the company’s description of the reported experiences. The survey does not establish the cause of an individual woman’s skin concern or separate hormonal effects from general ageing.
On the trial side, the release does not state the sample size or participant demographics beyond menopausal status. It does not specify randomisation, blinding, treatment schedule or statistical methods. Trial registration and adverse-event information are also absent. The results are described as data on file without a cited peer-reviewed publication.
The dermal-thickness figures are relative percentage changes without baseline or absolute measurements, confidence intervals or p-values. The release supplies no separate numerical results for the décolletage. It does not describe a comparison with no treatment or other options.
These omissions mean the announcement cannot establish an optimal treatment sequence or provide a full safety assessment. Satisfaction also answers a different question from safety: participants describing a result as natural-looking is not proof that a procedure is appropriate for every woman. The release is a starting point for evaluating the treatments rather than a new clinical protocol.
The practical response is a better conversation about the skin change itself. If a concern appeared around perimenopause or menopause, its timing is useful information to raise with a clinician or dermatologist. That brings the hormonal transition into the history while leaving the assessment with a qualified professional.
Persistent dryness deserves attention in its own right. The AAD advises consulting a dermatologist when dryness continues or other skin concerns need assessment. An appointment can focus on what has changed and what support is appropriate, without making an aesthetic procedure the presumed destination.
The AAD’s routine-care guidance centres on daily broad-spectrum sunscreen rated SPF 30 or higher. It also recommends a mild cleanser and moisturiser for dry skin. These are non-product-specific recommendations, so the basic discussion need not begin with a brand-led treatment claim.
There is one distinction that should not get lost in an ageing discussion. The AAD cautions that a dark spot resembling an age spot can sometimes be skin cancer. It recommends having a dermatologist examine such spots before using an age-spot treatment.
For broader context, Refemina’s explanation of hormonal and other contributors to skin change keeps the focus on understanding the concern rather than assigning a single label.
Anyone considering treatment can discuss the following questions with a qualified clinician:
Those questions keep a consultation centred on the woman’s concern rather than the product sequence featured in a company announcement.
This research should make menopause a more explicit part of midlife skin consultations, with treatment choices following individual assessment rather than a survey headline.
Assessing a menopause-related skin claim starts with separating its explanation from the treatment being marketed, a distinction Refemina addresses through research-led editorial coverage. For women facing conflicting explanations for a changing body, its coverage places hormonal transition within the wider midlife picture rather than treating every skin concern as a hormone problem.
Follow Refemina for research-led insights on menopause, strength, metabolism, nutrition, skin, intimacy and confidence through midlife. New articles turn complex topics into clear, useful context.
Keep learning about the changes that shape energy, strength, confidence and wellbeing through midlife.
Explore Resources